127 related articles for article (PubMed ID: 18156625)
1. Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc gamma IIb receptor.
Mihaylova N; Voynova E; Tchorbanov A; Nikolova M; Michova A; Todorov T; Srebreva L; Taskov H; Vassilev T
Int Immunol; 2008 Feb; 20(2):165-75. PubMed ID: 18156625
[TBL] [Abstract][Full Text] [Related]
2. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice.
Tchorbanov AI; Voynova EN; Mihaylova NM; Todorov TA; Nikolova M; Yomtova VM; Chiang BL; Vassilev TL
Eur J Immunol; 2007 Dec; 37(12):3587-96. PubMed ID: 18034421
[TBL] [Abstract][Full Text] [Related]
3. Target silencing of disease-associated B-lymphocytes by chimeric molecules in SCID model of pristane-induced autoimmunity.
Dimitrova I; Gesheva V; Nikolova K; Mihaylova N; Todorov T; Nikolova M; Tchorbanov A
Lupus; 2010 Oct; 19(11):1261-71. PubMed ID: 20530521
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous engagement of FcgammaIIb and CD22 inhibitory receptors silences targeted B cells and suppresses autoimmune disease activity.
Mihaylova N; Voynova E; Tchorbanov A; Dolashka-Angelova P; Bayry J; Devreese B; Kaveri S; Vassilev T
Mol Immunol; 2009 Nov; 47(1):123-30. PubMed ID: 19243823
[TBL] [Abstract][Full Text] [Related]
5. Selective silencing of autoreactive B lymphocytes-Following the Nature's way.
Nikolova KA; Mihaylova NM; Voynova EN; Tchorbanov AI; Voll RE; Vassilev TL
Autoimmun Rev; 2010 Sep; 9(11):775-9. PubMed ID: 20601201
[TBL] [Abstract][Full Text] [Related]
6. An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes.
Voynova E; Tchorbanov A; Prechl J; Nikolova M; Baleva M; Erdei A; Vassilev T
Immunol Lett; 2008 Mar; 116(2):168-73. PubMed ID: 18262286
[TBL] [Abstract][Full Text] [Related]
7. Suppression of dsDNA-specific B lymphocytes reduces disease symptoms in SCID model of mouse lupus.
Gesheva V; Kerekov N; Nikolova K; Mihaylova N; Todorov T; Nikolova M; Tchorbanov A
Autoimmunity; 2014 May; 47(3):162-72. PubMed ID: 24502777
[TBL] [Abstract][Full Text] [Related]
8. FcgammaRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease.
Yajima K; Nakamura A; Sugahara A; Takai T
Eur J Immunol; 2003 Apr; 33(4):1020-9. PubMed ID: 12672068
[TBL] [Abstract][Full Text] [Related]
9. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
10. Targeted silencing of DNA-specific B cells combined with partial plasma cell depletion displays additive effects on delaying disease onset in lupus-prone mice.
Nikolova-Ganeva KA; Gesheva VV; Todorov TA; Voll RE; Vassilev TL
Clin Exp Immunol; 2013 Nov; 174(2):221-8. PubMed ID: 23808414
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.
Veri MC; Burke S; Huang L; Li H; Gorlatov S; Tuaillon N; Rainey GJ; Ciccarone V; Zhang T; Shah K; Jin L; Ning L; Minor T; Moore PA; Koenig S; Johnson S; Bonvini E
Arthritis Rheum; 2010 Jul; 62(7):1933-43. PubMed ID: 20506263
[TBL] [Abstract][Full Text] [Related]
12. Tonic B cell activation by Radioprotective105/MD-1 promotes disease progression in MRL/lpr mice.
Kobayashi T; Takahashi K; Nagai Y; Shibata T; Otani M; Izui S; Akira S; Gotoh Y; Kiyono H; Miyake K
Int Immunol; 2008 Jul; 20(7):881-91. PubMed ID: 18492657
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.
Veri MC; Gorlatov S; Li H; Burke S; Johnson S; Stavenhagen J; Stein KE; Bonvini E; Koenig S
Immunology; 2007 Jul; 121(3):392-404. PubMed ID: 17386079
[TBL] [Abstract][Full Text] [Related]
14. Restoration of tolerance in lupus by targeted inhibitory receptor expression.
McGaha TL; Sorrentino B; Ravetch JV
Science; 2005 Jan; 307(5709):590-3. PubMed ID: 15681388
[TBL] [Abstract][Full Text] [Related]
15. Synthetic peptides from mouse Fc receptor (MoFc gamma RII) that alter the binding of IgG to MoFc gamma RII.
Goldsmith EB; Erickson BW; Thompson NL
Biochemistry; 1997 Jan; 36(4):952-9. PubMed ID: 9020795
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus.
Dieker JW; Fransen JH; van Bavel CC; Briand JP; Jacobs CW; Muller S; Berden JH; van der Vlag J
Arthritis Rheum; 2007 Jun; 56(6):1921-33. PubMed ID: 17530637
[TBL] [Abstract][Full Text] [Related]
17. Characterization and crystallization of soluble human Fc gamma receptor II (CD32) isoforms produced in insect cells.
Sondermann P; Jacob U; Kutscher C; Frey J
Biochemistry; 1999 Jun; 38(26):8469-77. PubMed ID: 10387093
[TBL] [Abstract][Full Text] [Related]
18. [Effects of HS1-associated protein X-1 on the lupus activities: experiment with MRL/lpr lupus-like mice].
Zhai ZF; Zhou CL; Zhong BY; Ao JH; Hao F
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):406-10. PubMed ID: 18581896
[TBL] [Abstract][Full Text] [Related]
19. Low-level signaling generated by FcgammaRIIB-B cell receptor co-ligation establishes a state of global B cell receptor nonresponsiveness.
Preissler MT; Kaiser L; Drake JR; Gosselin EJ
Immunol Invest; 2005; 34(1):53-70. PubMed ID: 15773572
[TBL] [Abstract][Full Text] [Related]
20. Fc gamma RII-B1 regulates the presentation of B cell receptor-bound antigens.
Minskoff SA; Matter K; Mellman I
J Immunol; 1998 Sep; 161(5):2079-83. PubMed ID: 9725196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
